Journey Medical Corp

Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. It s focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its sales and marketing model. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Journey Medical Corp reports revenue growth and profitability in Q1

Journey Medical Corp's Q1 2024 performance reflects revenue growth and profitability driven by key products and cost management.
The company's strengths lie in the success of DFD-29, financial stability, and strategic business development initiatives.
Challenges include maintaining market share, successful DFD-29 launch, and balancing new product pursuits with existing offerings.
Opportunities include leveraging DFD-29 for sustained profitability, exploring new product opportunities, and expanding global presence.

Journey Medical Corp (DERM) reports robust Q2 results and eyes FDA approval for growth

Journey Medical Corp (DERM) demonstrated strong revenue performance and cost management in Q2 2024, positioning for future growth.
The company's focus on innovation, IP protection, and financial discipline bodes well for long-term sustainability and profitability.
Despite challenges in a competitive market, Journey Medical Corp (DERM) remains optimistic about FDA approvals and revenue diversification.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Fortress Biotech

Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29 Provides additional capital for general corporate purposes including funding to support the potential launch of DFD-29

Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million

Amphastar Pharma

Aquestive Therapeutics Inc

Centessa Pharmaceuticals PLC

Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.

What Awaits These 4 Drug Stocks That More Than Doubled in 2023?

Fusion Pharmaceuticals

Lyra Therapeutics

Novo Nordisk

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.

Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?

Alpine Immune Sciences

Aurinia Pharmaceuticals

Harpoon Therapeutics Inc

Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year

G-III Apparel Group

JAKKS Pacific

Insight Enterprises

Wingstop

WING, JAKK, NSIT, GIII and DERM are five stocks with explosive relative price strength.

Relative Price Strength Makes These 5 Stocks Excellent Buys

Journey Medical shows a meteoric rise, led by strategic focus on dermatology and product innovation. Despite challenges, DFD-29, an oral treatment for rosacea, shows promise, potentially revolutionizing moderate to severe cases. Q3 2023 financials reveal significant growth, driven by licensing deals, though volatility in core business operations persists.

The Strategic Evolution Of Journey Medical In Dermatological Care

Journey Medical (DERM) plans to submit a new drug application (NDA) to the FDA for DFD-29 to treat rosacea in adults by 2023-end. Stock rises.

Journey Medical (DERM) Up on Update for Skin Disease Candidate

Beacon Roofing Supply

TopBuild

Shift4 Payments

With the Fed likely to trim interest rates along with seasonal tailwinds, growth stocks like Beacon Roofing Supply (BECN), TopBuild (BLD), Journey Medical (DERM) and Shift4 Payments (FOUR) are poised to gain strength.

4 Growth Stocks to Buy Ahead of a Strong Year-End Rally

On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023 On track to submit a New Drug Application to the FDA for DFD-29 around year-end of 2023

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

Does Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice

Journey Medical Corporation (DERM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'

Journey Medical Corporation (NASDAQ:DERM ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Interim Chief Financial Officer Dr. Srinivas Sidgiddi - Vice President, Research and Development Ramsey Allous - General Counsel and Corporate Secretary Conference Call Participants Scott Henry - ROTH Capital Andy Fleszar - B. Riley Operator Ladies and gentlemen, thank you for standing by.

Journey Medical Corporation (DERM) Q3 2023 Earnings Call Transcript

Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission to FDA for DFD-29 anticipated in the fourth quarter of 2023 SCOTTSDALE, Ariz., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced data from a comparative bioavailability (bridging) study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.

Journey Medical (DERM) & Maruho Ink Deal for Qbrexza Asia Rights

SCOTTSDALE, Ariz., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced it has entered into an exclusive license agreement (the “Agreement”) with Maruho Co., Ltd.

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

Journey Medical Corporation (NASDAQ:DERM ) Q2 2023 Earnings Conference Call August 8, 2023 4:00 PM ET Company Participants Matt Blazei - CoreIR Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Interim Chief Financial Officer Srinivas Sidgiddi - Vice President of R&D Neal Bhatia - Director of Clinical Dermatology at Therapeutics Clinical Research Conference Call Participants Scott Henry - Roth capital Kalpit Patel - B. Riley Securities Operator Ladies and Gentleman, thank you for standing by.

Journey Medical Corporation (DERM) Q2 2023 Earnings Call Transcript

The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.

Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%

SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that it expects topline results from the two Phase 3 multicenter, randomized, double-blind, parallel-group, active-comparator and placebo-controlled clinical trials, MVOR-1 (Minocycline versus Oracea® in Rosacea-1) and MVOR-2 (Minocycline versus Oracea in Rosacea-2), evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of moderate to severe papulopustular rosacea (“PPR”), to be announced the week of July 10, 2023. DFD-29 is being developed for the treatment of PPR in collaboration with Dr. Reddy's Laboratories Ltd.

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of Jul

News for Journey Medical Corp Stock (DERM)